12 November 2015: Clinical Research
VEGF Gene Polymorphisms are Associated with Risk of Tetralogy of Fallot
Xiang Li A , Chao-Liang Liu B , Xiao-Xia Li C , Qing-Chen Li D , Li-Ming Ma E , Gao-Li Liu F
DOI: 10.12659/MSM.894568
Med Sci Monit 2015; 21:3474-3482
Abstract
BACKGROUND: The aim of this study was to investigate associations of 3 common polymorphisms in the VEGF gene, –2578C>A, –634C>G, and 936C>T, with risk of tetralogy of Fallot (TOF) in Chinese Han children.
MATERIAL AND METHODS: From January 2010 to June 2013, a total of 400 pediatric subjects were recruited, including 160 cases with TOF (TOF group) and 240 healthy controls (control group). The genotypes of 3 common VEGF polymorphisms, –2578C>A, –634C>G, and 936C>T, were analyzed by polymerase chain reaction restriction fragment length polymorphism. All data were analyzed with SPSS 18.0 software.
RESULTS: No significant differences were observed in body mass index or sex between TOF patients and controls (both P>0.05), but significant differences in age and family history of TOF were observed between the 2 groups (both P<0.05). The AA genotype in -2578C>A of VEGF was correlated with a significantly increased risk of TOF, and TOF risk in A allele carrier was 1.54-fold higher than that of C allele carrier (OR=1.54, 95%CI=1.14–2.09, P=0.005); the statistical significance was still present after Bonferroni correction (Pc=0.045). GG genotype in –634C>G of VEGF gene was also associated with an increased risk of TOF, and TOF risk in patients with G allele was 1.62-fold higher compared to patients with C allele (OR=1.62, 95%CI=1.19–2.21, P=0.002); the statistical significance was still present after Bonferroni correction (Pc=0.018). Interestingly, T allele in VEGF 936C>T polymorphism is associated with a decreased TOF risk (OR=0.65, 95%CI=0.49–0.87, P=0.003, the statistical significance was still present after Bonferroni correction (Pc=0.027). The result of logistic regression analysis revealed that –2578C>A, –634C>G, and 936C>T genotypes are independently related to the prevalence of TOF (all P<0.05).
CONCLUSIONS: Our results confirmed that VEGF genetic polymorphisms, –2578C>A and –634C>G, may be associated with an increased TOF risk, while 936C>T polymorphism may be associated with decreased TOF risk.
Keywords: Child, Biomarkers - blood, Alleles, Child, Preschool, Echocardiography, Doppler, Gene Frequency, Genotype, Heterozygote, Linkage Disequilibrium, Polymerase Chain Reaction, Polymorphism, Restriction Fragment Length, Polymorphism, Single Nucleotide, Risk Factors, Software, Tetralogy of Fallot - ultrasonography, Vascular Endothelial Growth Factor A - genetics
Background
Tetralogy of Fallot (TOF) is the most frequently form of cyanotic heart defect or cyanotic congenital heart disease, and is the major cause of blue baby syndrome [1]. TOF is characterized by a misalignment of the conal septum, resulting in a rightward deviation of the aorta, which may lead to a large ventricular septal defect and varying degrees of right ventricular outflow tract narrowing [2]. The incidence of TOF is estimated at 5~7 per 10 000 live births and TOF accounts for 5~7% of all congenital heart lesions [3]. Importantly, patients with TOF generally receive surgical repair in the first year of life, with additional requirement of surgical intervention as the child grows [4]. Since the first description of procedures in the 1950s, the diagnosis, surgical treatment, and postoperative care of TOF have significantly improved; hence, patients born with TOF can now expect to survive to adulthood [5–7]. However, despite excellent short- and medium-term survival rates, the 30-year actuarial survival for patients repaired before their 5th birthday is 90% of the expected survival rate and the annualized risk of death triples in the third postoperative decade [8]. The exact pathophysiology of TOF is not well understood, but both genetic and environmental factors play major roles in TOF [9,10]. Viral infections, urticarial vasculitis, radiation exposure, lifestyle, and other environmental factors are associated with a high risk of TOF [11]. Recent evidence suggests that
Vascular endothelial growth factor (VEGF) belongs to a sub-family of the platelet-derived growth factors and is a prominent endothelial cell-specific mitogen and inducer of vascular permeability, and is an important signaling molecule involved in vasculogenesis and angiogenesis [14]. In the angiogenic network, the VEGF are by far the best characterized and has been implicated in the pathogenesis of coronary artery disease and in its complication, acute myocardial infarction [15]. As a multifunctional cytokine, VEGF exerts a variety of essential biological effects on vascular endothelium [16]. VEGF induces angiogenesis in various physiological and pathological conditions, such as normal embryogenesis, compensatory angiogenesis, wound-healing, and in tumor growth and metastasis [14,17]. Hypoxia up-regulates VEGF gene expression, which has tremendous physiological implications for a wide variety of pathological conditions in humans [18]. Adequate VEGF serum levels are essential for heart development, and alterations in VEGF levels may contribute to cardiovascular developmental defects [19,20]. In this context, up-regulated VEGF levels, during the development of right ventricular outflow tract, result in abnormal development of both cushion and myocardial structures [21,22]. Therefore, genetic polymorphisms in
Material and Methods
STUDY SUBJECTS AND ETHICS STATEMENT:
A total of 160 Chinese Han children with TOF were recruited for this study as the case group (TOF group) at the Department of Cardiovascular, Affiliated Hospital of Jining Medical University between January 2010 and June 2013. The TOF patients exhibited typical clinical symptoms and were all diagnosed with color Doppler echocardiography and surgery. Patients with abnormalities other than cardiovascular abnormalities were excluded. There were no abnormalities found by karyotype analysis of the included TOF patients. Among the 160 TOF children, 103 patients were males and 57 patients were females, with an average age of 4.27±1.93 years old (age range, 1 to 8 years). Another group of 240 healthy Han children, who received health examination at the medical examination center of our hospital during the same period, were selected as the control group. The Han children who suffered from congenital heart disease or other cardiac structural abnormalities, as confirmed by clinical manifestations and echocardiography, were excluded from this study. The control group included 148 males and 92 females, with an average age of 5.68±2.17 years old (age range, 2 to 10 years). There were no significant differences in age or sex between the TOF group and control group (P>0.05). This study was approved by the Ethics Committee of the Affiliated Hospital of Jining Medical University. All parents of all included Han children signed the informed consent prior to the study and the study conformed to the Declaration of Helsinki [30].
DNA EXTRACTION:
A total of 2 ml peripheral venous blood from all included subjects was drawn in the morning, following an overnight fast, and was placed in ethylenediamine tetraacetic acid (EDTA)-containing tubes for anticoagulation, and stored at −20°C until further use. The 2-ml blood samples were centrifuged at 2500r/m for 5 min to serum and cells, and the collected serum was evenly split into 3-ml cryotubes and stored at −20°C for later use. Genomic DNA was extracted from leukocytes using the conventional saturated phenol-chloroform extraction method. The concentration and purity of DNA was measured and the isolated genomic DNA was stored at −20°C for further use.
SNP SELECTION AND PRIMER DESIGN:
We investigated 3 relevant SNP candidates in the VEGF gene. All SNP sequences selected for genotyping were initially identified using the HapMap database (http://www.hapmap.org/). The linkage disequilibrium of VEGF polymorphisms is illustrated in Figure 1. The SNP genotypes of the VEGF functional polymorphic loci, −2578C>A, −634C>G, and 936C>T, were detected by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). The full-length VEGF gene sequence was retrieved from GenBank (Accession Number AF 437895) and, based on the gene sequence, the PCR amplification primers for each polymorphic loci were designed using Primer 5.0 software (Takara, Dalian), as shown in Table 1.
POLYMERASE CHAIN REACTION RESTRICTION FRAGMENT LENGTH POLYMORPHISM (PCR-RFLP):
The gradient PCR was performed using a Thermocycler MJPTC-200 PCR System. The PCR amplification of the genetic polymorphisms of VEGF was performed after determining the optimal annealing temperature. The PCR reaction system in a 15-μl volume contained the following components: 50 ng genomic DNA, 12.5 pmol of each primer, 0.1 mml of each nucleotide, l0×PCR buffer (50 mml KCl, 10 mml TrisHCl, 0.1% Triton X-100, 1.5 mml MgCl2, and 1.0 U Taq polymerase). Reaction conditions of PCR were as follows: initial denaturation at 95°C for 5 min, denaturation at 95°C for 30 s, annealing at annealing temperature, which were 53°C −2578>A), 67°C (−634C>G), and 53°C (936C>T), respectively, for 40 s, and extension at 72°C for 45 s. After 34 cycles of amplification, final extension was at 72°C for 10 min. The PCR amplification product were first purified and 5 μl of the purified PCR amplification products were digested with 5 U of restriction enzymes Bg1II, BsmFI, and NlaIII (Shanghai Sangon Biotech, Shanghai, China) to distinguish between the genetic polymorphisms of VEGF. Restriction digestions were performed under standard digestion conditions, with an overnight incubation at 37°C. The results were analyzed by 3.0% agarose gel electrophoresis to detect PCR fragment pattern, and individual genotypes were determined from the size of the bands. The restriction enzymes for each locus are shown in Table 1.
GENOTYPING:
Restriction fragment length polymorphism (RFLP) was employed to detect the genetic polymorphisms of −2578C>A, −634C>G, and 936C>T in
STATISTICAL ANALYSIS:
All data were analyzed with SPSS17.0 software (SPSS, Chicago, IL, USA). Measurement data are expressed as mean ± standard deviation (Mean ±SD) and
Results
BASELINE CHARACTERISTICS:
The baseline characteristics of TOF patients and normal controls are illustrated in Table 2. No statistically significant differences in body mass index (BMI) or sex distribution were observed between the TOF group and the healthy control group (both P>0.05). Importantly, there was a significant difference in age and in the family history of TOF between the 2 groups (both P<0.05).
:
The electrophoresis patterns for the genotypes of VEGF genetic polymorphisms are as illustrated in Figures 2–4. The PCR-RFLP results of VEGF rs699947 (−2578C>A) polymorphism showed that AA genotype showed 2 fragments of 202 bp and 122 bp, and the CA genotype showed 3 fragments of 324 bp, 202 bp, and 122 bp, while CC genotype remained undigested. The VEGF rs2010963 (−634C>G) polymorphism showed 3 patterns: CC genotype with a single band of 180 bp, CG genotype with 180 bp, 120 bp, and 60 bp fragments, and GG genotype with 60 bp and 120 bp fragments. Further, the CC genotype of VEGF rs3025039 (936C>T) remained undigested, while the TT genotype showed 2 fragments of 86 bp and 112 bp fragments and CT genotype showed 3 fragments of 198 bp, 86 bp, and 112 bp.
The distribution of genotypes and allele frequencies of the 3 VEGF gene polymorphisms, −2578C>A, −634C>G, and 936C>T, are shown in Table 3. The genotypes and allele frequencies of VEGF −2578C>A, −634C>G, and 936C>T polymorphisms were in accordance with HWE, suggesting that each gene frequency had reached equilibrium and the selected sample represented the population (P>0.05). The frequency of mutant AA genotype in VEGF −2578C>A polymorphism in TOF group was significantly higher than the control group (48.8% vs. 32.9%, P=0.042), and the statistical significance was still present after Bonferroni correction (Pc=0.372). The A allele frequency in −2578C>A in the TOF group was markedly higher than that observed in the control group (71.2% vs. 61.7%, P=0.005), and the statistical significance was still present after Bonferroni correction (Pc=0.045). The AA+CA genotype frequency of the TOF group was higher than the control group (93.8% vs. 90.4%), with no statistical difference (P=0.235). Additionally, the GG genotype frequency of VEGF −634C>G in TOF group was significantly higher than the control group (53.8% vs. 36.7%, P=0.031), and the statistical significance was still present after Bonferroni correction (Pc=0.279). The G allele frequency in −634C>G in the TOF group was higher than in the control group (72.8% vs. 62.3%, P=0.002); the statistical significance was still present after Bonferroni correction (Pc=0.018). The GG+CG frequency on −634C>G in the TOF group was higher than in the control group (91.9% vs. 81.9%), but with no statistical difference (P=0.206). Conversely, the frequencies of TT genotype and T allele in VEGF 936C>T in TOF group were both significantly lower than in the control group (TT genotype: 41.9% vs. 54.6%, P=0.030, Pc=0.270; T allele: 48.1% vs. 58.7%, P=0.003, Pc=0.027). However, there was no statistically significant difference in TT+CT genotypes frequencies between the 2 groups (54.4% vs. 62.9%, P=0.088).
LINKAGE ANALYSIS OF SNP IN VEGF GENE:
Linkage disequilibrium was evaluated by D and r2 values. It is showed linkage disequilibrium when r2 >0.33 (Table 4). The rs699947 and rs2010963 locus presented linkage disequilibrium (r2=0.694), while the rs2010963and rs3025039 locus did not (r2=0.198).
:
Multiple logistic regression analysis was carried out to calculate the adjusted odds ratio. The TOF was the dependent variable, and the AA, CC, and TT genotype of VEGF −2578C>A, −634G>C, and 936C>T were the independent variables. The multivariate logistic regression analysis results showed that the mutable gene of −2578C>A and −634C>G polymorphisms are independently related to the TOF risk (OR=1.951, 95%CI=1.280~2.974, P=0.002; OR=2.144, 95%CI=1.411~3.258, P<0.001), and the TT genotypes of 936C>T are also associated with TOF risk (OR=0.590, 95%CI=0.389–0.894, P=0.013) (Table 5).
Discussion
In this study, we examined the correlations of
The gene coding for VEGF is affected by common, functionally important genetic polymorphisms associated with cardiovascular disease and are early predictors of congenital heart disease. Among the most important polymorphisms are: −2578C>A (rs699947), located in the promoter region; −634G>C (rs2010963), located in exon 1; and +936C>T (rs3025039), located in exon 8, in the 5′ untranslated region [45]. In the current study, we found that the frequency of AA genotype in −2578C>A in the TOF group was significantly higher than in the control group, and the TOF risk of patients with A allele carrier was 1.54-fold higher than that of C allele carrier, suggesting that the AA genotype and A allele in −2578C>A polymorphism may be a potential risk factor for TOF development. Further, the frequency of GG genotype in −634C>G in the TOF group was also significantly higher than the control group, and the risk of TOF of the patients with G allele was 1.62-fold higher than in patients with C allele, implying that the GG genotype and G allele in −634C>G in polymorphism may be correlated with the increased risk of TOF. However, T allele in 936C>T polymorphism decreased TOF risk, indicating that the T allele may be a protective factor for TOF. All of the above results had statistical significance after Bonferroni correction. Douvaras et al. showed that the −634C>G polymorphism of
There are some limitations in the present study. First of all, the sample sizes of our study were relatively small, which may reduce the strength of our conclusions. Secondly, the statistical power was not conducted in this study, which also decreased the power of our study.
Conclusions
Our results provide strong evidence that the polymorphisms of
References
1. Apitz C, Webb GD, Redington AN, Tetralogy of Fallot: Lancet, 2009; 374; 1462-71, pmid: 19683809
2. Witters I, De Groot R, Van Loo K, Tetralogy of Fallot with coronary artery to pulmonary artery fistula: Prenat Diagn, 2014; 34; 1345-46, pmid: 25123106
3. Bittel DC, Kibiryeva N, Marshall JA, O’Brien JE, MicroRNA-421 Dysregulation is associated with tetralogy of fallot: Cells, 2014; 3; 713-23, pmid: 25257024
4. Tsze DS, Vitberg YM, Berezow J, Treatment of tetralogy of Fallot hypoxic spell with intranasal fentanyl: Pediatrics, 2014; 134; e266-69, pmid: 24936003
5. Miyazaki A, Sakaguchi H, Ohuchi H, Efficacy of hemodynamic-based management of tachyarrhythmia after repair of tetralogy of Fallot: Circ J, 2012; 76; 2855-62, pmid: 22893279
6. Luijten LW, van den Bosch E, Duppen N, Long-term outcomes of transatrial-transpulmonary repair of tetralogy of Fallot: Eur J Cardiothorac Surg, 2015; 47; 527-34, pmid: 24801339
7. Ylitalo P, Nieminen H, Pitkanen OM, Need of transannular patch in tetralogy of Fallot surgery carries a higher risk of reoperation but has no impact on late survival: results of Fallot repair in Finland: Eur J Cardiothorac Surg, 2015; 48(1); 91-97, pmid: 25326015
8. Pandya B, Quail MA, Cullen S, Clinical issues and outcomes in adults following repair of tetralogy of fallot: Curr Treat Options Cardiovasc Med, 2013; 15; 602-14, pmid: 23873585
9. Rauch R, Hofbeck M, Zweier C, Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot: J Med Genet, 2010; 47; 321-31, pmid: 19948535
10. Kuciene R, Dulskiene V, Selected environmental risk factors and congenital heart defects: Medicina (Kaunas), 2008; 44; 827-32, pmid: 19124958
11. Gupta R, Tetralogy of Fallot: Rapid Review Anesthesiology Oral Boards, 2013; 117-22
12. Lambrechts D, Devriendt K, Driscoll DA, Low expression VEGF haplotype increases the risk for tetralogy of Fallot: a family based association study: J Med Genet, 2005; 42; 519-22, pmid: 15937089
13. Silversides CK, Lionel AC, Costain G, Rare copy number variations in adults with tetralogy of Fallot implicate novel risk gene pathways: PLoS Genet, 2012; 8; e1002843, pmid: 22912587
14. Ferrara N, Vascular endothelial growth factor: Arterioscler Thromb Vasc Biol, 2009; 29; 789-91, pmid: 19164810
15. Petrovic D, The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease: Cardiovasc Hematol Agents Med Chem, 2010; 8; 47-54, pmid: 20210775
16. Poh CK, Shi Z, Lim TY: Biomaterials, 2010; 31; 1578-85, pmid: 19963265
17. Bao P, Kodra A, Tomic-Canic M, The role of vascular endothelial growth factor in wound healing: J Surg Res, 2009; 153; 347-58, pmid: 19027922
18. Osada-Oka M, Ikeda T, Imaoka S, VEGF-enhanced proliferation under hypoxia by an autocrine mechanism in human vascular smooth muscle cells: J Atheroscler Thromb, 2008; 15; 26-33, pmid: 18270456
19. Stankunas K, Ma GK, Kuhnert FJ, VEGF signaling has distinct spatiotemporal roles during heart valve development: Dev Biol, 2010; 347; 325-36, pmid: 20816797
20. Vannay A, Vasarhelyi B, Kornyei M, Single-nucleotide polymorphisms of VEGF gene are associated with risk of congenital valvuloseptal heart defects: Am Heart J, 2006; 151; 878-81, pmid: 16569553
21. Hsieh PC, Davis ME, Lisowski LK, Lee RT, Endothelial-cardiomyocyte interactions in cardiac development and repair: Annu Rev Physiol, 2006; 68; 51-66, pmid: 16460266
22. Villefranc JA, Nicoli S, Bentley K, A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development: Development, 2013; 140; 1497-506, pmid: 23462469
23. Vincenti V, Cassano C, Rocchi M, Persico G, Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3: Circulation, 1996; 93; 1493-95, pmid: 8608615
24. Jacobs EJ, Feigelson HS, Bain EB, Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort: Breast Cancer Res, 2006; 8; R22, pmid: 16613616
25. Bulgu Y, Cetin GO, Caner V, Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration in a Turkish population: Int J Ophthalmol, 2014; 7; 773-77, pmid: 25349791
26. Smedts HP, Isaacs A, de Costa D, VEGF polymorphisms are associated with endocardial cushion defects: a family-based case-control study: Pediatr Res, 2010; 67; 23-28, pmid: 19816237
27. Awata T, Inoue K, Kurihara S, A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes: Diabetes, 2002; 51; 1635-39, pmid: 11978667
28. Petrovic D, Verhovec R, Globocnik Petrovic M, Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes: Cardiology, 2007; 107; 291-95, pmid: 17264508
29. Richards AA, Garg V, Genetics of congenital heart disease: Curr Cardiol Rev, 2010; 6; 91-97, pmid: 21532774
30. World Medical A, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects: JAMA, 2013; 310; 2191-94, pmid: 24141714
31. Gaengel K, Genove G, Armulik A, Betsholtz C, Endothelial-mural cell signaling in vascular development and angiogenesis: Arterioscler Thromb Vasc Biol, 2009; 29; 630-38, pmid: 19164813
32. Holderfield MT, Hughes CC, Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis: Circ Res, 2008; 102; 637-52, pmid: 18369162
33. Cohen ED, Tian Y, Morrisey EE, Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor self-renewal: Development, 2008; 135; 789-98, pmid: 18263841
34. High FA, Epstein JA, The multifaceted role of Notch in cardiac development and disease: Nat Rev Genet, 2008; 9; 49-61, pmid: 18071321
35. Wagner M, Siddiqui MA, Signal transduction in early heart development (II): ventricular chamber specification, trabeculation, and heart valve formation: Exp Biol Med (Maywood), 2007; 232; 866-80, pmid: 17609502
36. Armstrong EJ, Bischoff J, Heart valve development: endothelial cell signaling and differentiation: Circ Res, 2004; 95; 459-70, pmid: 15345668
37. Ferrara N, Gerber HP, LeCouter J, The biology of VEGF and its receptors: Nat Med, 2003; 9; 669-76, pmid: 12778165
38. Yang S, Piao J, Jin L, Zhou Y, Does pretreatment of bone marrow mesenchymal stem cells with 5-azacytidine or double intravenous infusion improve their therapeutic potential for dilated cardiomyopathy?: Med Sci Monit Basic Res, 2013; 19; 20-31, pmid: 23314418
39. Aydin HI, Yozgat Y, Demirkaya E, Correlation between vascular endothelial growth factor and leptin in children with cyanotic congenital heart disease: Turk J Pediatr, 2007; 49; 360-64, pmid: 18246735
40. Baghdady Y, Hussein Y, Shehata M, Vascular endothelial growth factor in children with cyanotic and acyanotic and congenital heart disease: Arch Med Sci, 2010; 6; 221-25, pmid: 22371751
41. Hamada H, Ebata R, Higashi K: Int J Cardiol, 2007; 120; 66-71, pmid: 17126928
42. Hutson MR, Kirby ML, Model systems for the study of heart development and disease. Cardiac neural crest and conotruncal malformations: Semin Cell Dev Biol, 2007; 18; 101-10, pmid: 17224285
43. Combs MD, Yutzey KE, Heart valve development: regulatory networks in development and disease: Circ Res, 2009; 105; 408-21, pmid: 19713546
44. van den Akker NM, Molin DG, Peters PP, Tetralogy of fallot and alterations in vascular endothelial growth factor-A signaling and notch signaling in mouse embryos solely expressing the VEGF120 isoform: Circ Res, 2007; 100; 842-49, pmid: 17332426
45. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE, Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production: Cytokine, 2000; 12; 1232-35, pmid: 10930302
46. Douvaras P, Antonatos DG, Kekou K, Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction: Cardiology, 2009; 114; 11-18, pmid: 19332989
47. Xie J, Yi L, Xu ZF, VEGF C-634G polymorphism is associated with protection from isolated ventricular septal defect: case-control and TDT studies: Eur J Hum Genet, 2007; 15; 1246-51, pmid: 17625508
48. Krippl P, Langsenlehner U, Renner W, A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk: Int J Cancer, 2003; 106; 468-71, pmid: 12845639
49. Renner W, Kotschan S, Hoffmann C, A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels: J Vasc Res, 2000; 37; 443-48, pmid: 11146397
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






